BackLyell Immunopharma Overview

Lyell Immunopharma Net Tangible Assets

Track Lyell Immunopharma's net tangible assets ($230M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$233.81M
↓ 21.78% YoYΔ $-65.11M vs prior year quarter

Peer average

Loading

Lyell Immunopharma Net Tangible Assets History

Loading

Lyell Immunopharma vs. peers: Net Tangible Assets Comparison

Loading

Lyell Immunopharma Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Lyell Immunopharma (LYEL) FAQ

As of the most recent data (June 2026), LYEL shows a net tangible assets of $230M. That compares with $300M in the prior-year period — down 21.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LYEL's net tangible assets is now $230M (was $300M) — a 21.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lyell Immunopharma is outperforming or lagging.

Tracking LYEL's net tangible assets over time shows whether Lyell Immunopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $230M That compares with $300M in the prior-year period — down 21.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Lyell Immunopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $230M) with ownership activity and broader fundamentals.

Lyell Immunopharma's net tangible assets is $230M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.